ストックスクリーナーアプリを入手
32.74
1.84%
0.59
アフターアワーズ：
33.20
0.46
+1.41%
前日終値:
$32.15
開ける：
$32.3
24時間の取引高:
418.46K
Relative Volume:
0.55
時価総額：
$1.42B
収益：
$384.10M
当期純損益:
$-9.07M
株価収益率:
-233.86
EPS:
-0.14
ネットキャッシュフロー:
$11.10M
1週間 パフォーマンス:
-0.64%
1か月 パフォーマンス:
+16.55%
6か月 パフォーマンス:
+66.19%
1年 パフォーマンス:
+30.08%
1日の値動き範囲:
$32.00
$32.87
1週間の範囲:
$31.78
$33.98
52週間の値動き範囲:
$17.82
$33.98
Kiniksa Pharmaceuticals International Plc Stock (KNSA) Company Profile
名前
Kiniksa Pharmaceuticals International Plc
セクター
電話
(781) 431-9100
住所
23 OLD BOND STREET, FLOOR 3, LONDON
KNSA を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
KNSA
Kiniksa Pharmaceuticals International Plc
|
32.74 | 2.38B | 384.10M | -9.07M | 11.10M | -0.14 |
|
ZTS
Zoetis Inc
|
149.02 | 65.30B | 9.39B | 2.61B | 2.22B | 5.81 |
|
TAK
Takeda Pharmaceutical Co Adr
|
14.43 | 45.60B | 29.98B | 958.27M | 5.31B | 0.2964 |
|
HLN
Haleon Plc Adr
|
9.47 | 42.82B | 14.35B | 1.85B | 0 | 0.4023 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
16.42 | 18.78B | 16.54B | -1.64B | 749.00M | -1.45 |
|
UTHR
United Therapeutics Corp
|
300.43 | 13.64B | 2.99B | 1.21B | 1.13B | 25.06 |
Kiniksa Pharmaceuticals International Plc Stock (KNSA) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-03-13 | 開始されました | Citigroup | Buy |
| 2024-09-13 | 開始されました | Jefferies | Buy |
| 2024-05-03 | 開始されました | Wells Fargo | Overweight |
| 2020-06-29 | 繰り返されました | BofA Securities | Buy |
| 2020-04-01 | 開始されました | BofA/Merrill | Buy |
| 2019-03-11 | 開始されました | Barclays | Overweight |
| 2018-12-12 | 繰り返されました | Wedbush | Outperform |
| 2018-06-19 | 開始されました | JMP Securities | Mkt Outperform |
すべてを表示
Kiniksa Pharmaceuticals International Plc (KNSA) 最新ニュース
Eben Tessari Sells 138,614 Shares of Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) Stock - MarketBeat
Michael R. Megna Sells 17,000 Shares of Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) Stock - MarketBeat
Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) CFO Sells $621,259.21 in Stock - MarketBeat
John F. Paolini Sells 29,325 Shares of Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) Stock - MarketBeat
Kiniksa Pharmaceuticals International (NASDAQ:KNSA) Sets New 12-Month HighShould You Buy? - MarketBeat
BIT Capital GmbH Takes $264,000 Position in Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) - MarketBeat
Kiniksa Pharmaceuticals International, plc (KNSA) Is Up 21.46% in One Week: What You Should Know - Yahoo Finance
Kiniksa Pharmaceuticals International (NASDAQ:KNSA) Upgraded at Wall Street Zen - Defense World
Wedbush Issues Positive Outlook for KNSA Earnings - MarketBeat
Kiniksa Pharmaceuticals surges 11.01% on Arcalyst's market penetration - AInvest
Victory Capital Management Inc. Makes New Investment in Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) - MarketBeat
Does Kiniksa Pharmaceuticals International, plc (KNSA) Have the Potential to Rally 35.96% as Wall Street Analysts Expect? - MSN
Kiniksa Pharmaceuticals International (NASDAQ:KNSA) Sets New 12-Month High After Earnings Beat - MarketBeat
Equities Analysts Set Expectations for KNSA Q3 Earnings - Defense World
Why Kiniksa Pharmaceuticals International, plc (KNSA) Might be Well Poised for a Surge - Yahoo Finance
Here's Why Momentum in Kiniksa Pharmaceuticals International, plc (KNSA) Should Keep going - Yahoo Finance
Victory Capital Management Inc. Takes $1.18 Million Position in Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) - Defense World
Kiniksa Pharmaceuticals Achieves 52% YoY Growth in Q2 2025, Raises Revenue Guidance - AInvest
Kiniksa Pharmaceuticals International, plc (KNSA) Tops Q2 Earnings and Revenue Estimates - MSN
Kiniksa raises ARCALYST 2025 revenue guidance to $625M-$640M as patient penetration rises - MSN
Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) Q2 2025 Earnings Call Transcript - Insider Monkey
Kiniksa Pharmaceuticals International Second Quarter 2025 Earnings: Beats Expectations - Yahoo Finance
Kiniksa Pharmaceuticals International PLC (KNSA) Q2 2025 Earnings Call Highlights: Record ... - Yahoo Finance
Kiniksa Pharmaceuticals International PLC (KNSA) Q2 2025 Earnings Call Highlights: Record ... By GuruFocus - Investing.com Canada
Kiniksa Pharmaceuticals International (NASDAQ:KNSA) Hits New 1-Year High After Strong Earnings - Defense World
Kiniksa Pharmaceuticals Reports Strong Q2 2025 Growth - TipRanks
Kiniksa: Jefferies maintains Buy, raises PT to $54 from $45. - AInvest
Kiniksa Pharmaceuticals Reports Second Quarter 2025 Financial Results and Recent Portfolio Execution - GlobeNewswire
Kiniksa Pharmaceuticals Q2 2025 Earnings Call Transcript: Key Highlights and Financial Results - AInvest
Kiniksa Pharmaceuticals stock hits 52-week high at 30.8 USD By Investing.com - Investing.com Nigeria
Kiniksa Pharmaceuticals International Q2 2025 Earnings Call Transcript - MarketBeat
Kiniksa Pharmaceuticals Reports Q2 2025 Financial Results with 52% Growth in ARCALYST Revenue and Updates on Clinical Trials - Quiver Quantitative
Kiniksa Crushes Earnings: ARCALYST Sales Jump 52%, Company Raises 2025 Revenue Target to $640M - Stock Titan
Kiniksa Pharmaceuticals Q2 2025 Earnings Preview: $0.22 EPS, $145.21M Revenue Expected - AInvest
Cwm LLC Purchases 19,828 Shares of Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) - MarketBeat
Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) Given Average Rating of “Buy” by Analysts - Defense World
Analysts Set Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) PT at $39.67 - MarketBeat
Kiniksa Pharmaceuticals Announces Q2 2025 Financial Results Conference Call. - AInvest
Kiniksa Pharmaceuticals International PLC expected to post earnings of 18 cents a shareEarnings Preview - TradingView
Cwm LLC Has $491,000 Holdings in Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) - Defense World
Kiniksa Pharmaceuticals to Report Second Quarter 2025 Financial Results on July 29, 2025 - GlobeNewswire
Kiniksa Pharmaceuticals Q2 2025 Earnings: Key Financial Results Coming July 29How to Join - Stock Titan
Cerity Partners LLC Boosts Stock Holdings in Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) - Defense World
Kiniksa Pharmaceuticals Ltd. Stock Analysis and ForecastExceptional gains - Autocar Professional
BlackRock, Inc. Significantly Reduces Holdings in Kiniksa Pharmaceuticals International PLC - GuruFocus
Kiniksa Pharmaceuticals International Plc (KNSA) 財務データ
収益
当期純利益
現金流量
EPS
0.64%
2.58%
大文字化:
|
ボリューム (24 時間):